Phosphodiesterase-4 (PDE-4) Inhibitors: Roflumilast, a PDE-4 inhibitor, has been shown to reduce airway inflammation and COPD exacerbations without adversely affecting glucose metabolism. Here, PDE4A is linked to chronic obstructive pulmonary disease.